Evidence map›Paper›PMID 37434095›Full record

ArticleAnnals of hematology2023

More than 2% circulating plasma cells as a prognostic biomarker in a large cohort of patients with newly-diagnosed multiple myeloma.

Mengru Tian, Xinyue Liang, Weiling Xu, Xingcheng Yi, Tingting Yue, Yingjie Zhang, Shanshan Yu, Yurong Yan, Zhongli Hu, Nan Zhang and 6 more

Abstract readLetter
PubMed Publisher
In one paragraph

Article in Annals of hematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Mengru Tian *Hematology Department, Cancer Center, First Hospital of Jilin University, 71 Xinmin Street, Changchun, 130012, Jilin, China.
Xinyue Liang *Hematology Department, Cancer Center, First Hospital of Jilin University, 71 Xinmin Street, Changchun, 130012, Jilin, China.
Weiling XuRadiology Department, First Hospital of Jilin University, Changchun, Jilin, China.
Xingcheng YiLaboratory of Cancer Precision Medicine, First Hospital of Jilin University, 519 Dongminzhu Street, Changchun, 130061, Jilin, China.
Tingting YueHematology Department, Cancer Center, First Hospital of Jilin University, 71 Xinmin Street, Changchun, 130012, Jilin, China.
Yingjie ZhangHematology Department, Cancer Center, First Hospital of Jilin University, 71 Xinmin Street, Changchun, 130012, Jilin, China.
Shanshan YuHematology Department, Cancer Center, First Hospital of Jilin University, 71 Xinmin Street, Changchun, 130012, Jilin, China.
Yurong YanHematology Department, Cancer Center, First Hospital of Jilin University, 71 Xinmin Street, Changchun, 130012, Jilin, China.
Zhongli HuHematology Department, Cancer Center, First Hospital of Jilin University, 71 Xinmin Street, Changchun, 130012, Jilin, China.
Nan ZhangHematology Department, Cancer Center, First Hospital of Jilin University, 71 Xinmin Street, Changchun, 130012, Jilin, China.
Jingxuan WangHematology Department, Cancer Center, First Hospital of Jilin University, 71 Xinmin Street, Changchun, 130012, Jilin, China.
Rui HuHematology Department, Cancer Center, First Hospital of Jilin University, 71 Xinmin Street, Changchun, 130012, Jilin, China.
Xiaoxiao SunHematology Department, Cancer Center, First Hospital of Jilin University, 71 Xinmin Street, Changchun, 130012, Jilin, China.
Yuanyuan NieHematology Department, Cancer Center, First Hospital of Jilin University, 71 Xinmin Street, Changchun, 130012, Jilin, China.
Yun DaiLaboratory of Cancer Precision Medicine, First Hospital of Jilin University, 519 Dongminzhu Street, Changchun, 130061, Jilin, China. daiyun@jlu.edu.cn.ORCID http://orcid.org/0000-0003-2285-0818
Fengyan JinHematology Department, Cancer Center, First Hospital of Jilin University, 71 Xinmin Street, Changchun, 130012, Jilin, China. fengyanjin@jlu.edu.cn.ORCID http://orcid.org/0000-0003-2288-556X

Funding

Jilin Scientific and Technological Development Program 20190201042JCJilin Scientific and Technological Development Program 20190201163JCJilin Scientific and Technological Development Program 20210509010RQNational Natural Science Foundation of China 81471165National Natural Science Foundation of China 81670189National Natural Science Foundation of China 81670190National Natural Science Foundation of China 81870160National Natural Science Foundation of China 81971108National Natural Science Foundation of China 82270207
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Multiple MyelomaBiomarkers, TumorHumansPlasma CellsPrognosisBiomarkers, Tumor

Identifiers

PMID37434095

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.